Affimed Investor Relations Material
Latest events
Study Update
Affimed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Affimed N.V.
Access all reports
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company operates through two segments, Affimed Therapeutics, and Redoxa GmbH. It develops therapies based on its proprietary TandAb platform to unleash the innate power of the immune system by harnessing the functionality of natural killer cells and T-cells for the treatment of cancer.
The company has strategic partnerships with Genentech Inc.; Merck KGaA and Pfizer Inc.; Novartis Institutes for BioMedical Research, Inc.; Celgene Corporation; Bayer Pharma AG; MorphoSys AG; Incyte Corporation; Amgen Inc.; Hoffmann-La Roche ltd; Sanofi S.A.; and Bristol-Myers Squibb Company. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany
Key slides for Affimed N.V.
Study Update
Affimed N.V.
Study Update
Affimed N.V.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
AFMD
Country
🇺🇸 United States